Vol. 23/No. 11 | Oncology Live®

June 14, 2022

Mehmet A. Bilen, MD, and a panel of renal cell carcinoma experts discuss the preferred treatment options for patients with intermediate-risk or high-risk advanced renal cell carcinoma and the clinical features that may influence their decisions.

June 10, 2022

B7-H3, a member of the same protein family as PD-L1, has garnered attention as one of a slew of alternative targets riding the wave of success of immune checkpoint inhibitors in cancer immunotherapy.

June 09, 2022

Highly effective tools, such as immunotherapeutic agents, have emerged for the treatment of patients with a wide range of malignancies.

June 08, 2022

The BRUIN CLL-321 trial is evaluating pirtobrutinib monotherapy compared with investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously received covalent BTK inhibitor treatment.

June 02, 2022

For the 10th consecutive year, OncLive® is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

June 01, 2022

New systemic regimens are being integrated into the treatment paradigm for resectable non–small cell lung cancer in the neoadjuvant and adjuvant settings, expanding options for patients with earlier-stage disease who face a challenging prognosis.

June 01, 2022

Heather McArthur, MD, MPH, described how the data from DESTINY-Breast03 reshapes the treatment landscape and offers added benefit to patients with brain metastases.

May 31, 2022

There are serious concerns about textbook descriptions of peer review, specifically within the realm of clinical research, which pose a threat to both the objectivity of the field of investigative medicine and, perhaps most importantly, to the public’s support of clinical science.